		Hepatitis C		Prescribing Practitioner: NPI:							
		Enrollment Form Physician Offices Call: 855-460-7928 Fax: 888-777-5645		Supervising Physician:					NPI:		
SENDERRA				Address:					Tax ID:	Tax ID:	
Specialty Pharmacy				Office	e :						
1301 E. Arapaho Rd., Ste. 101 Richardson, TX 75081		1 ax. 000-///-3045		Contact:							
This prescription form is to be sent & received via fax PATIENT INFORMATION											
Name:			F/	AIIEN		DOB:		SS	S#:		
Street:		City:			State		ZIP:				
Tel:		Alt. Tel:					Wt.: Ht.:		t.: Ht.:		
	□ English □ Spanish □ Other: · · · ·										
□ New □ Refill Ship by:		·			Ship to: Patient's Home Doctor's Office Other:						
Drug	Strength	Directions & Quantity *30 mg dose is intended for use with strong CYP3A inhibitors*									
Daklinza®	□ _{60 mg} Tablet □ ₉₀	Take 1 tablet P 28)	PO QD with or without food (Quantity: *90 mg dose is intended for use with moderate CYP3A inducers*								
Epclusa [®]	Epclusa®			Take 1 tablet PO QD with or without food (Quantity: 28)							
Harvoni [®]	400/90 mg Tab		Take 1 tablet PO QD with or without food (Quantity: 28)								
Mavyret™	100/40 mg Tab	Take 3 tablets PO QD with food (Quantity: 84)									
Sovaldi [®]	□400 mg Tablet (sofosbuvir)	Take 1 tablet PO QD with or without food (Quantity: 28)									
Viekira Pak®	12.5/75/50 mg (ombitasvir/paritaprevir/ritonav	Take 2 pink tablets PO QD (morning) and 1 beige tablet PO BID (morning and evening) with a meal (Quantity: 56/56)									
Vosevi [®]	400/100/100 m (sofosbuvir/velpatasvir/vox	Take 1 tablet PO QD with food (Quantity: 28)									
Zepatier® 550/100 mg Tablet (elbasvir/grazoprevir)			Take 1 tablet PO QD with or without food (Quantity: 28)								
RIBAVIRIN PRODUCTS											
☐ Take 400 mg Q		□ Copegus® Tablet □ Moderiba™ Tablet □ Ribasphere® Rib				Ribasphere [®] RibaPak [®]					
Take 600 mg Q							_				
☐ Takemg Q	AM,mg QPM (Quantity:		Ribavrin Tablet ☐ Ribavrin Capsule ☐ Moderiba [™] Dose Pack								
MEDICAL INFORMATION ***PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES & LAB WORK REGARDING THERAPY***											
			L CARD, FRONT	AND B	ACK, AS WEL		_	_	RK REGARDING THEF	RAPY***	
Diagnosis: □B18.2 Chronic Hepatitis C Virus (HCV) Date of Diagnosis: / / Treatment Naïve? □ Yes □ No											
Genotype: $\Box_1 \Box_2 \Box_3 \Box_4 \Box_5 \Box_6$ Subtype: $\Box_A \Box_B \Box_{A/B} \Box_{N/A}$						Baselin	e viral load:	IL	J/mL Date://		
Cirrhosis: ☐ Yes ☐ No (if yes, is it: ☐ compensated ☐ decompensated) Co-infection status: ☐ HIV ☐ HBV ☐ N/A											
Degree of liver fibrosis: ☐ F0 ☐ F1 ☐ F2 ☐ F3 ☐ F4 Polymorphism(s): ☐ NS5A ☐ IL28B ☐ Q80K ☐ N/A								□ _{Q80K} □ _{N/A}			
Prior	Date(s) of treatment:			Treatm	ent weeks:		Treatment Response:				
						·	□ Null □ Partial □ Relapsed				
		_				·		□Incomplet	te Null Partial Re	lapsed	
Allergies: Expected Duration of Therapy: \$\square\$ 8 weeks \$\square\$ 12 weeks \$\square\$ 24 weeks											
Additional Clinical Information:											
PRESCRIBING PRACTITIONER SIGNATURE To Prescribing Practitioner: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and											
Prescribing Practitioner: Prescribing Practitioner: Date:											
Date.											
CONFIDENTIALITY NOTICE IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the											

named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.